Response and progression in recurrent malignant glioma (Journal article)
Hess, K. R./ Wong, E. T./ Jaeckle, K. A./ Kyritsis, A. P./ Levin, V. A./ Prados, M. D./ Yung, W. K.
In this article we report the results of a study of the relationship between response and progression in 375 patients with recurrent glioma enrolled in phase II chemotherapy trials. We reviewed the records of patients from 8 consecutive phase II trials, including 225 patients with recurrent glioblastoma multiforme and 150 with recurrent anaplastic astrocytoma. Median age was 45 years (range, 15-82) and median Karnofsky performance score was 80 (range, 60-100). Forty-one patients (11%) had more than two prior resections and/or more than two prior chemotherapy regimens. Best response was complete (n = 1) or partial (n = 33) in 34 patients (9%). Median time to response was 14 weeks, and median response duration was 44 weeks. Simon-Makuch estimates for 52-week progression-free survival for patients progression-free at 13 weeks were 48% for response and 28% for nonresponse. When response was treated as a time-dependent covariate in a Cox proportional hazards regression analysis, response was associated with significantly lower failure rates (hazard ratio 0.5; 95% confidence interval 0.3-0.8; P = 0.0016). This study showed that response in recurrent glioma is associated with a significant reduction in progression rates.
|Institution and School/Department of submitter:||Πανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικής|
|Keywords:||Actuarial Analysis,Adolescent,Adult,Aged,Aged, 80 and over,Antineoplastic Combined Chemotherapy Protocols/*therapeutic use,Astrocytoma/drug therapy/mortality/radiotherapy,Brain Neoplasms/*drug therapy/mortality/radiotherapy,Carboplatin/administration & dosage,Combined Modality Therapy,Disease Progression,Disease-Free Survival,Eflornithine/administration & dosage,Female,Fluorouracil/administration & dosage,Glioblastoma/drug therapy/mortality/radiotherapy,Glioma/*drug therapy/mortality/radiotherapy,Humans,Interferon-beta/administration & dosage,Male,Menogaril/administration & dosage,Middle Aged,Neoplasm Recurrence, Local/*drug therapy/mortality,Procarbazine/administration & dosage,Prognosis,Proportional Hazards Models,Texas/epidemiology,Treatment Outcome,Tretinoin/administration & dosage|
|Appears in Collections:||Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά)|
Files in This Item:
There are no files associated with this item.
Please use this identifier to cite or link to this item:This item is a favorite for 0 people.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.